Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

Emmie de Wit; Friederike Feldmann; Eva Horne; Atsushi Okumura; Elisabetta Cameroni; Elaine Haddock; Greg Saturday; Dana Scott; Robin Gopal; Maria Zambon; Davide Corti; Heinz Feldmann

doi:10.1016/j.antiviral.2019.01.016

Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

Emmie de Wit, Friederike Feldmann, Eva Horne, Atsushi Okumura, Elisabetta Cameroni, Elaine Haddock, Greg Saturday, Dana Scott, Robin Gopal, Maria Zambon, Davide Corti, Heinz Feldmann^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.

Original language	English
Pages (from-to)	70-74
Number of pages	5
Journal	Antiviral Research
Volume	163
DOIs	https://doi.org/10.1016/j.antiviral.2019.01.016
Publication status	Published - Mar 2019

Bibliographical note

Funding Information:
The authors would like to thank the members of the Rocky Mountain Veterinary Branch (DIR, NIAID, NIH) for their assistance with this study. This work was supported in part by the Intramural Research Program of NIAID, NIH and federal funds from the Biomedical Advanced Research and Development Authority , Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.

Keywords

Common marmoset
LCA60
MERS-CoV
Neutralizing monoclonal antibody
Prophylaxis
Treatment

Access to Document

10.1016/j.antiviral.2019.01.016

Cite this

@article{d7a7eaaae9c74c34b3a9d2f7280d931e,

title = "Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset",

abstract = "Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.",

keywords = "Common marmoset, LCA60, MERS-CoV, Neutralizing monoclonal antibody, Prophylaxis, Treatment",

author = "{de Wit}, Emmie and Friederike Feldmann and Eva Horne and Atsushi Okumura and Elisabetta Cameroni and Elaine Haddock and Greg Saturday and Dana Scott and Robin Gopal and Maria Zambon and Davide Corti and Heinz Feldmann",

note = "Funding Information: The authors would like to thank the members of the Rocky Mountain Veterinary Branch (DIR, NIAID, NIH) for their assistance with this study. This work was supported in part by the Intramural Research Program of NIAID, NIH and federal funds from the Biomedical Advanced Research and Development Authority , Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services. ",

year = "2019",

month = mar,

doi = "10.1016/j.antiviral.2019.01.016",

language = "English",

volume = "163",

pages = "70--74",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

}

TY - JOUR

T1 - Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

AU - de Wit, Emmie

AU - Feldmann, Friederike

AU - Horne, Eva

AU - Okumura, Atsushi

AU - Cameroni, Elisabetta

AU - Haddock, Elaine

AU - Saturday, Greg

AU - Scott, Dana

AU - Gopal, Robin

AU - Zambon, Maria

AU - Corti, Davide

AU - Feldmann, Heinz

N1 - Funding Information: The authors would like to thank the members of the Rocky Mountain Veterinary Branch (DIR, NIAID, NIH) for their assistance with this study. This work was supported in part by the Intramural Research Program of NIAID, NIH and federal funds from the Biomedical Advanced Research and Development Authority , Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.

PY - 2019/3

Y1 - 2019/3

N2 - Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.

AB - Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.

KW - Common marmoset

KW - LCA60

KW - MERS-CoV

KW - Neutralizing monoclonal antibody

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85060438434&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2019.01.016

DO - 10.1016/j.antiviral.2019.01.016

M3 - Article

C2 - 30684561

AN - SCOPUS:85060438434

SN - 0166-3542

VL - 163

SP - 70

EP - 74

JO - Antiviral Research

JF - Antiviral Research

ER -

Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this